Loading patent…
AssigneeEberhard Karls Universität Tübingen Medizinische Fakultät
InventorsJuliane Walz, Annika Nelde, Hans-Georg Rammensee, Heiko Schuster
Estimating the term…
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
A pharmaceutical composition for the treatment, prevention or diagnosis of hematological neoplasms, comprising at least one peptide which binds to class II molecules of the major histocompatibility complex (MHC class II molecules) or induces T cells cross-reacting with said peptide, and a pharmaceutically acceptable carrier, wherein said at least one peptide comprises an amino acid sequence which is selected from the group consisting of:
A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
A recombinant host cell comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
Dependencies are inferred from the claim text.